Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455506 · ClinicalTrials.gov registry record · Phase 1
PRO#0118: Decitabine Plus Mini Flu-Bu
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01455506 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 20 participants.
The verdict
NCT01455506, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single institution study of combining decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation. A study population of 20 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible to receive allogeneic hematopoietic stem cell transplantation according to the eligibility criteria will be consented and enrolled. Subjects will receive treatment with decitabine followed by reduced intensity fludarabine and busulfan prior to allogeneic stem cell transplantation. Subjects will be followed until 1 year post transplantation to assess stability of engraftment, toxicity, progression free survival, and disease response
Interventions
- DRUG Decitabine plus Fludarabine and Busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01455506
The ClinicalTrials.gov registry entry for NCT01455506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine plus Fludarabine and Busulfan is the first listed.
NCT01455506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01455506 about?
NCT01455506 is a clinical study titled "PRO#0118: Decitabine Plus Mini Flu-Bu". This is a single institution study of combining decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation. A study population of 20 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible t...
What is the current status of trial NCT01455506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01455506?
The interventions under investigation include: Decitabine plus Fludarabine and Busulfan (DRUG).
Who is sponsoring clinical trial NCT01455506?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.